www.bloomberg.com
Bausch Health’s stock declined after its Obeticholic Acid therapy failed to achieve primary endpoints in two Phase 3 trials for metabolic dysfunction-associated steatohepatitis (MASH). The study results did not meet the regulatory threshold for statistical significance regarding fibrosis improvement, casting doubt on the drug’s potential approval and future revenue. This setback impacts Bausch Health’s pipeline as they continue to navigate challenges in developing treatments for advanced liver disease. Investors reacted negatively to the news, marking a significant hurdle for the company’s pharmaceutical division.
Read More
